Axonics, Inc. (NASDAQ:AXNX) Receives $69.57 Consensus PT from Brokerages

Shares of Axonics, Inc. (NASDAQ:AXNX) have received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $69.57.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Monday, August 5th.

Institutional Trading of Axonics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXNX. AQR Capital Management LLC boosted its stake in shares of Axonics by 0.9% during the 2nd quarter. AQR Capital Management LLC now owns 18,337 shares of the company’s stock worth $1,233,000 after purchasing an additional 161 shares during the last quarter. Xponance Inc. boosted its position in Axonics by 7.5% during the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after acquiring an additional 225 shares during the last quarter. Headlands Technologies LLC grew its stake in Axonics by 31.1% in the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after acquiring an additional 265 shares during the period. Arizona State Retirement System grew its stake in Axonics by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock worth $960,000 after acquiring an additional 355 shares during the period. Finally, Scholtz & Company LLC raised its holdings in Axonics by 7.8% in the 4th quarter. Scholtz & Company LLC now owns 4,985 shares of the company’s stock valued at $310,000 after acquiring an additional 360 shares during the last quarter. Hedge funds and other institutional investors own 99.48% of the company’s stock.

Axonics Stock Down 0.1 %

AXNX opened at $69.45 on Thursday. Axonics has a 52 week low of $48.30 and a 52 week high of $69.91. The business has a 50 day moving average price of $68.82 and a two-hundred day moving average price of $68.01. The company has a market cap of $3.54 billion, a PE ratio of -217.03 and a beta of 0.81.

Axonics (NASDAQ:AXNX) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.10 by $0.03. The business had revenue of $114.57 million during the quarter, compared to analysts’ expectations of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.15) earnings per share. As a group, sell-side analysts expect that Axonics will post 0.24 EPS for the current fiscal year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.